
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
The American Journal of Managed Care
over 29 years ago
The Political Economy of Capitated Managed Careover 29 years ago
Appropriate and Necessary Healthcare: New Language for a New Eraover 29 years ago
Managing Asthma Care





